Format

Send to

Choose Destination
Oncoimmunology. 2016 Dec 23;6(2):e1273302. doi: 10.1080/2162402X.2016.1273302. eCollection 2017.

CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy.

Author information

1
Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
2
Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, NY, USA.

Abstract

PD-L1/2 expression in solid tumors inhibits chimeric antigen receptor (CAR) T-cell efficacy. A PD-1 dominant negative receptor expressed in CAR T cells provides cell-intrinsic checkpoint blockade and augments antitumor efficacy. A combinatorial immunotherapeutic strategy of combining CAR T cells with checkpoint blockade is a promising treatment approach for solid tumors.

KEYWORDS:

Adoptive T-cell therapy; PD-1 blockade; breast cancer; immunosuppression; lung cancer; mesothelioma; tumor microenvironment

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center